IRBM CSO Carlo Toniatti on the Evolving CRO Role in Drug Development, Emerging Approaches in Oncology & the Potential of AI
Source: Pharma Boardroom
In an 80,000 m2 site 20 miles from Rome, young researchers from around the world work day and night making history. They have played a key role in the development of the Covid-19 vaccine, after the Jenner Institute (expert in coronavirus) sent them the viral inoculum and asked them for help. IRBM in Pomezia (Rome) has in fact a great experience in adenovirus, the viral vector. «We are producing and shipping the doses: phase III is underway» say Piero Di Lorenzo, President of IRBM, «if everything goes as planned, and it’s a big if, the first doses could be available in Italy between November and December». For IRBM – 43 million turnover reflecting the activity of a centre of excellence – this is an epoch-making challenge.